Skip to main content
Isofol Medical logo

Isofol Medical — Investor Relations & Filings

Ticker · ISOFOL ISIN · SE0009581051 LEI · 549300MCXYAHG7VBHX75 ST Professional, scientific and technical activities
Open in API
Filings indexed 208 across all filing types
Latest filing 2024-03-20 Major Shareholding Noti…
Country SE Sweden
Listing ST ISOFOL

About Isofol Medical

https://isofolmedical.com/

Isofol Medical is a clinical-stage biotechnology company dedicated to improving treatments for severe forms of cancer. The company's primary focus is the development of its lead drug candidate, arfolitixorin. This next-generation, folate-based therapy is designed to enhance the efficacy of standard cancer treatments, such as chemotherapy. Arfolitixorin is the active metabolite of commonly used folate-based drugs, potentially offering a therapeutic benefit to a broader patient population by bypassing complex metabolic activation steps. The company's goal is to help more patients respond better to their treatment, thereby improving their prognosis.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding, specifically a 'Sell' transaction by Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension, resulting in their holding dropping below the 10% limit. The structure, use of terms like 'major shareholding notification', 'Percentage of voting rights', and the specific reporting of share quantities and dates strongly indicate a regulatory filing concerning significant ownership changes. This aligns perfectly with the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2024-03-20 English
Isofols japanska partner Solasia har beslutat att intensifiera sitt engagemang i den kliniska utvecklingen av arfolitixorin
Regulatory Filings Classification · 100% confidence The document is a press release dated March 19, 2024, announcing that Isofol's Japanese partner, Solasia, will intensify its involvement in the clinical development of arfolitixorin. It details strategic updates and mentions an investor meeting scheduled for the same day where the clinical development plan will be presented. The text is a formal announcement of business/partnership activity and strategic updates, rather than a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). Since it is a formal announcement regarding strategic business development and partnership commitment related to drug development, it fits best under Regulatory Filings (RNS) as a general corporate announcement, or potentially a Capital/Financing Update (CAP) if the partnership implies significant financial commitment, but RNS is the most appropriate general category for non-standard corporate news releases that aren't explicitly covered elsewhere. Given the content focuses on partnership commitment and clinical strategy updates, and it is structured as a standard press release announcing corporate news, RNS (Regulatory Filings) is the most suitable general classification for this type of announcement that doesn't fit the more specific financial or governance codes.
2024-03-19 Swedish
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin
Regulatory Filings Classification · 100% confidence The document is a press release announcing an update on a collaboration between Isofol Medical AB and its Japanese partner, Solasia, regarding the clinical development of a drug candidate (arfolitixorin). It details Solasia's commitment to the ongoing development program, including defining clinical trial designs. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement concerning business strategy and partnership updates, which fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially a general 'LTR' if it were related to legal proceedings, but here it is purely operational/partnership news. Given the options, RNS serves as the best general corporate announcement fallback for non-standard, material news that isn't explicitly covered by other codes like DIV, CAP, or MANG. It is not a presentation (IP) or a management discussion (MDA).
2024-03-19 English
Isofol presenterar en klinisk utvecklingsplan för arfolitixorin
Investor Presentation Classification · 85% confidence The document is a press release from Isofol Medical AB announcing a new clinical development strategy and a clinical trial plan for their drug candidate, arfolitixorin. It details the company's strategic direction, clinical trial design, and mentions an upcoming investor meeting. While it discusses strategy, it is a corporate announcement of a business/clinical update rather than a formal investor presentation deck, a quarterly financial report, or a regulatory filing. Given the nature of the announcement regarding corporate strategy and clinical development, it fits best under 'Regulatory Filings' (RNS) as a general corporate announcement.
2024-03-19 Swedish
Isofol presents a clinical development plan for arfolitixorin
Investor Presentation Classification · 95% confidence The document is a press release from Isofol Medical AB announcing a new clinical development plan for their drug candidate, arfolitixorin. It details the strategy, the design of a planned phase I/II study, and mentions an upcoming investor meeting to discuss these plans. While it mentions an investor meeting, the document itself is a corporate announcement regarding business strategy and clinical development, which falls under general regulatory announcements (RNS) as it does not fit into specific categories like earnings releases, financial reports, or proxy statements.
2024-03-19 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ISOFOL MEDICAL AB (PUBL) BOKSLUTSKOMMUNIKÉ 2023' (Year-End Report 2023). It contains comprehensive financial data for the fourth quarter and the full year 2023, including income statements, cash flow, and management commentary on business trends, clinical study results, and future strategy. It is a substantive financial report for a period shorter than a full fiscal year (in this case, the year-end report covering the final quarter and annual summary), fitting the definition of an Interim/Quarterly Report. Q4 2023
2024-02-20 Swedish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.